173 related articles for article (PubMed ID: 23240674)
21. [Immunohistochemical study of endometrial stromal sarcoma and smooth-muscle tumors of the uterus].
Farah-Klibi F; Ben Hamouda S; Ben Romdhane S; Sfar R; Koubaa A; Ben Jilani S; Zermani R
J Gynecol Obstet Biol Reprod (Paris); 2008 Sep; 37(5):457-62. PubMed ID: 18565690
[TBL] [Abstract][Full Text] [Related]
22. Frequency of known gene rearrangements in endometrial stromal tumors.
Chiang S; Ali R; Melnyk N; McAlpine JN; Huntsman DG; Gilks CB; Lee CH; Oliva E
Am J Surg Pathol; 2011 Sep; 35(9):1364-72. PubMed ID: 21836477
[TBL] [Abstract][Full Text] [Related]
23. A well circumscribed uterine endometrial stromal tumor with smooth muscle differentiation recurred as a low grade endometrial stromal sarcoma: is tumor margin enough for the diagnosis?
Song JS; Lee SR; Kim KR
Pathol Int; 2012 May; 62(5):363-5. PubMed ID: 22524669
[No Abstract] [Full Text] [Related]
24. Role of the Immunohistochemical ZEB1 Expression in Uterine Mesenchymal Neoplasms.
Çelik M; Çelik ZE
Int J Surg Pathol; 2022 Aug; 30(5):520-527. PubMed ID: 34994578
[TBL] [Abstract][Full Text] [Related]
25. Epithelioid smooth muscle tumors of the uterus do not express CD1a: a potential immunohistochemical adjunct in their distinction from uterine perivascular epithelioid cell tumors.
Fadare O; Liang SX
Ann Diagn Pathol; 2008 Dec; 12(6):401-5. PubMed ID: 18995203
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemistry as a diagnostic aid in the interpretation of unusual mesenchymal tumors of the uterus.
Devaney K; Tavassoli FA
Mod Pathol; 1991 Mar; 4(2):225-31. PubMed ID: 1710807
[TBL] [Abstract][Full Text] [Related]
27. Apoptotic and cell cycle regulatory markers in uterine leiomyosarcoma.
Leiser AL; Anderson SE; Nonaka D; Chuai S; Olshen AB; Chi DS; Soslow RA
Gynecol Oncol; 2006 Apr; 101(1):86-91. PubMed ID: 16289259
[TBL] [Abstract][Full Text] [Related]
28. Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma.
Pautier P; Genestie C; Rey A; Morice P; Roche B; Lhommé C; Haie-Meder C; Duvillard P
Cancer; 2000 Mar; 88(6):1425-31. PubMed ID: 10717626
[TBL] [Abstract][Full Text] [Related]
29. Smooth muscle tumours of the uterine corpus: a clinicopathologic study with immunohistochemical aspects.
Waldmann J; Stachs A; Terpe H; Stropahl G; Makovitzky J
Anticancer Res; 2005; 25(3A):1559-65. PubMed ID: 16033061
[TBL] [Abstract][Full Text] [Related]
30. Advances in the diagnosis and treatment of uterine sarcomas.
Dizon DS; Birrer MJ
Discov Med; 2014 Jun; 17(96):339-45. PubMed ID: 24979254
[TBL] [Abstract][Full Text] [Related]
31. Prognoses and prognostic factors of carcinosarcoma, endometrial stromal sarcoma and uterine leiomyosarcoma: a comparison with uterine endometrial adenocarcinoma.
Akahira J; Tokunaga H; Toyoshima M; Takano T; Nagase S; Yoshinaga K; Tase T; Wada Y; Ito K; Niikura H; Yamada H; Sato A; Sasano H; Yaegashi N
Oncology; 2006; 71(5-6):333-40. PubMed ID: 17690557
[TBL] [Abstract][Full Text] [Related]
32. DOG1 immunoreactivity in uterine leiomyosarcomas.
Sah SP; McCluggage WG
J Clin Pathol; 2013 Jan; 66(1):40-3. PubMed ID: 23038686
[TBL] [Abstract][Full Text] [Related]
33. High levels of cellular retinol binding protein-1 expression in leiomyosarcoma: possible implications for diagnostic evaluation.
Orlandi A; Francesconi A; Clément S; Ropraz P; Spagnoli LG; Gabbiani G
Virchows Arch; 2002 Jul; 441(1):31-40. PubMed ID: 12111198
[TBL] [Abstract][Full Text] [Related]
34. Prognostic factors in uterine sarcoma.
Gadducci A
Best Pract Res Clin Obstet Gynaecol; 2011 Dec; 25(6):783-95. PubMed ID: 21764643
[TBL] [Abstract][Full Text] [Related]
35. Cyclooxygenase-2 is an independent predictor of poor prognosis in uterine leiomyosarcomas.
Lee CH; Roh JW; Choi JS; Kang S; Park IA; Chung HH; Jeon YT; Kim JW; Park NH; Kang SB; Song YS
Int J Gynecol Cancer; 2011 May; 21(4):668-72. PubMed ID: 21412163
[TBL] [Abstract][Full Text] [Related]
36. Pathology of uterine leiomyosarcomas and smooth muscle tumours of uncertain malignant potential.
Ip PP; Cheung AN
Best Pract Res Clin Obstet Gynaecol; 2011 Dec; 25(6):691-704. PubMed ID: 21865091
[TBL] [Abstract][Full Text] [Related]
37. Expression of the O-linked N-acetylglucosamine containing epitope H in normal myometrium and uterine smooth muscle cell tumors.
Sgantzos MN; Galani V; Arvanitis LD; Charchanti A; Psathas P; Nakou M; Havaki S; Kallioras V; Marinos E; Vamvakopoulos NC; Kittas C
Pathol Res Pract; 2007; 203(1):31-7. PubMed ID: 17129677
[TBL] [Abstract][Full Text] [Related]
38. ERBB-2 gene overexpression and amplification in uterine sarcomas.
Amant F; Vloeberghs V; Woestenborghs H; Debiec-Rychter M; Verbist L; Moerman P; Vergote I
Gynecol Oncol; 2004 Dec; 95(3):583-7. PubMed ID: 15581967
[TBL] [Abstract][Full Text] [Related]
39. p53 immunohistochemical analysis of fusion-positive uterine sarcomas.
Mohammad N; Stewart CJR; Chiang S; Turashvili G; Dickson BC; Ng TL; Köbel M; McCluggage WG; Croce S; Lee CH
Histopathology; 2021 May; 78(6):805-813. PubMed ID: 33118176
[TBL] [Abstract][Full Text] [Related]
40. p53 immunoreactivity and mutation of the p53 gene in smooth muscle tumours of the uterine corpus.
Jeffers MD; Farquharson MA; Richmond JA; McNicol AM
J Pathol; 1995 Sep; 177(1):65-70. PubMed ID: 7472782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]